We’d love to hear your feedback on this activity. It helps us to continually improve our products.
Ublituximab is a novel glycoengineered monoclonal antibody treatment under investigation for relapsing remitting multiple sclerosis. Prof. Bruce Cree (UCSF Multiple Sclerosis Centre, San Francisco, CA, USA) discusses ublituximab’s novel mode of action, and the potential advantages of ublituximab compared with other antibodies targeting CD20-expressing B-cells in the relapsing multiple sclerosis (RMS). The abstract entitled ‘Disability […]
Dr Sharon Cohen joins touchNEUROLOGY to discuss the challenges in diagnosing Alzheimer’s disease (AD) at an early stage, the most exciting recent developments in diagnostic criteria, genetic testing, and neuroimaging techniques. Dr Cohen also talks through the recent developments in biomarker strategies for diagnosis and precision management of early AD. The presentation entitled: ‘Accelerating Progress […]
Aducanumab is a human monoclonal antibody targeting soluble and insoluble amyloid beta (Aβ) aggregates. Aducanumab was approved in June 2021 for the treatment of mild cognitive impairment due to Alzheimer’s disease or mild dementia due to Alzheimer’s disease by the FDA under the accelerated approval pathway. Dr Sharon Cohen (Toronto Memory Program, Toronto, Canada) discusses […]
Cenobamate is approved in the United States for focal-onset seizures (partial-onset seizures) in adults both as adjunctive and monotherapy. In the EU, cenobamate is approved as adjunctive therapy for focal-onset seizures with or without secondary generalization for adult patients who have not been adequately controlled with at least two antiseizure medications. Dr. William Rosenfeld (Comprehensive […]
The International Parkinson and Movement Disorder Society (MDS) is a professional society of clinicians, scientists, and other healthcare professionals, who are interested in Parkinson’s disease, related neurodegenerative and neurodevelopmental disorders, hyperkinetic movement disorders, and abnormalities in muscle tone and motor control. touchNEUROLOGY caught up with the MDS President, Prof. Francisco Cardoso, to discuss the upcoming […]
Ecopipam is an investigational first-in-class drug being evaluated for the treatment of children and adolescents with Tourette’s syndrome. Prof. Donald Gilbert (Cincinnati Children’s Hospital Medical Centre, Cincinnati, OH, USA) discusses the randomised, double-blind, placebo-controlled phase 2b study investigating ecopipam. The abstract entitled ‘Ecopipam in Children and Adolescents with Tourette Syndrome: Results from a Randomized, Double-Blind, […]
Aquaporin 4-immunoglobulin G (AQP4-IgG) plays a major role in the pathogenesis of neuromyelitis optica spectrum disorder (NMOSD). Prof. Jeffrey Bennett (University of Colorado School of Medicine, Aurora, CO, USA) discusses the challenges in the treatment of NMOSD. Questions: What are the challenges in the treatment of neuromyelitis optica spectrum disorder (NMOSD)? (0:14) What is the […]
Satralizumab is a humanized monoclonal antibody medication that is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease, with Aquaporin 4-immunoglobulin G (AQP4-IgG+) playing a major role in its pathogenesis. Prof. Jeffrey Bennett (University of Colorado School of Medicine, Aurora, CO, USA) discusses the outcomes of SAkuraSky and SAkuraStar studies […]
The limitations of the current treatment of acute migraine are said to be patient variability and migraine attack variability. Prof. Stewart Tepper (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) discusses the limitations of current treatments for acute migraine and how new treatments overcome these. The abstract entitled ‘Efficacy and Safety of AXS-07 (MoSEIC Meloxicam-Rizatriptan) for the […]
Get the latest clinical insights from touchNEUROLOGY